CBRS18089 / S1418 / Alissa Huston
Basic Study Information
Purpose:
This randomized phase III trial studies how well pembrolizumab works in treating patients
with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such
as pembrolizumab, may help the body's immune system attack the cancer, and may interfere
with the ability of tumor cells to grow and spread.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Alissa Huston
Study Contact Information
Study Coordinator: Lauren Mitchell
Email: lauren_mitchell@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search